Targeting KEAP1-Mutant NSCLC With Broad-Acting Glutamine Antagonist
Oncology Times (2022) 44(13):1,12

Targeting Glutamine Metabolism Enhances Tumor Specific Immunity by Modulating Suppressive Myeloid Cells
Journal of Clinical Investigation (2020) 131859

Tumor Microenvironment, Metabolism, and Immunotherapy
New England Journal of Medicine (2020) 382:869-887

Glutamine Blockade Induces Divergent Metabolic Programs to Overcome Tumor Immune Evasion
Science (2019) 366(6468):1013-1021

Tumor-targeted Delivery of 6-diazo-5-oxo-L-norleucine (DON) using Substituted Acetylated Lysine Prodrugs
Journal of Medicinal Chemistry (2019) 62 (7): 3524–3538

We’re Not “DON” Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine
Molecular Cancer Therapeutics (2018) 17(9) 1824-1832

N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders
Journal of Medicinal Chemistry (2016) 60 (16): 7186–7198